Date:7/7/2009

s Conducts Study on Phenoxodiol in Prostate Cancer II-58 Combination of Provenge(R) and Taxotere(R) Offer Better Results for HRPC Patients II-58 Ambrilia Reveals Results of PSP-94 Immunoassay Study for Cancer Therapy II-58 University of California's Analyses Support Dendreon's Active Cellular Immunotherapy II-59 Spectrum Announces Positive Outcome of Satraplatin Trial on HRPC Patients II-59 Panacea Pharmaceuticals Identifies Blood Protein for Early Prostate Cancer Detection II-60 Active Biotech Reveals Results of TASQ Phase I Study for Prostate Cancer II-61 Positive Results of Combined Hormone and Radiation Therapies in Locally Advanced Prostate Cancer II-61 Positive Results from Use of IMRT in Localized Prostate Cancer II-61 Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer Growth II-62 Sanofi's Taxotere Gains Approval from Nice of UK for Use in Late-Stage Prostate Cancer II-62 Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX302 II-63 Aeterna Zentaris's Ozarelix Phase II Trial Shows Positive Results II-63 Biomira Announces Results of Stimuvax Phase 2 Clinical Study II-64 Cytogen Receives FDA Clearance for CYT-500 IND Application II-64 US Researchers Unveils New Therapeutic Cancer Vaccine For Metastatic Prostate Cancer II-64 PNNL and IsoRay Develops Cesium-131 Seed for Treatment of Prostate Cancer II-65 6. Product Innovations/Introductions II-66 Speciality European Pharma Introduces Plenaxis II-66 Actavis Unveils Bicalutamide Tablets for Prostate Cancer in the European Markets II-66 Artemis to Introduce IGRT II-66 Immunomedics Introduces Immunotoxin for Treatment of Prostate and Lung Cancer II-66 Barr Unveils Generic Version of Proscar(R) Tablets II-67 IRX Therapeutics to Develop Vaccine for Prostate Cancer II-67 Actavis Introduce
'/>"/>

SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update